+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 3Years - 12Years
All Genders
ID07281079

Evaluating Orally Administered NNZ-2591 Compared to Placebo in Children Ages 3 to 12 With Phelan-McDermid Syndrome

Led by Neuren Pharmaceuticals Limited · Updated on 2026-09-28

160

Participants Needed

18

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of NNZ-2591 compared to a placebo in children aged 3 to 12 years with Phelan-McDermid Syndrome. This Phase 3, randomized, double-blind, placebo-controlled study aims to understand how NNZ-2591 may impact symptoms related to this genetic condition. After consent, participants enter a 4-week screening period to determine eligibility and baseline symptom levels. Eligible children are then randomly assigned to receive either NNZ-2591 or a matching placebo, both taken orally twice daily, for 13 weeks. Following treatment, there is a 2-week safety follow-up to monitor any side effects. Throughout the study, participants undergo various assessments including symptom severity scales and caregiver impressions to measure changes. Researchers evaluate the primary outcomes at week 13 using specific tools for symptom change and communication abilities. The total duration of participation is approximately 17 to 19 weeks, including screening, treatment, and follow-up.

CONDITIONS

Brief Title

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Research Team

M

Medical Information Lead

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here